OptimizeRx Q4 revenue $19.7M (-3% YoY); guides FY23 revenue growth at least 10%

OptimizeRx Corp

Q4 revenue $19.7M (-3% YoY), gross profit $12.5M (+1%), GAAP net loss $0.3M ($0.02 loss per share).
Non-GAAP net income $4.4M ($0.25 per diluted share).
FY22 revenue up 2%, generated $10.7M cash from ops, repurchased 1.2M shares at avg $16.49.
Exited 2022 with six RWD-AI deals; pipeline of several dozen.
FY23 guidance: revenue growth at least 10% YoY, gross margin 58-62%; Q1 revenue $11.5-13M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OptimizeRx Corp reported the fourth quarter and year ended December 31, 2022 results: revenue $19.7 million, net income GAAP net loss totaled $(0.3) million or $(0.02) per basic and diluted share, EPS $(0.02) per basic and diluted share. Guidance initiated.

Period: the fourth quarter and year ended December 31, 2022
Revenue: $19.7 million
Net income: GAAP net loss totaled $(0.3) million or $(0.02) per basic and diluted share
EPS: $(0.02) per basic and diluted share
Guidance: initiated
Result: preliminary results

Exact text from the filing

2 ea174846ex99-1_optimizerx.htm PRESS RELEASE, DATED MARCH 8, 2023 Exhibit 99.1 OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results - Q4 revenue of $19.7 million, down 3% year-over-year and up 30% quarter-over-quarter - Q4 gross profit increased 1% year-over-year to $12.5 million as gross margins increased from 61% to 63% -

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-018553

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.